PG 043
Alternative Names: AR17043/latanoprost - Alcon; PG-043Latest Information Update: 08 Oct 2024
Price :
$50 *
At a glance
- Originator Alcon
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 04 Sep 2024 Phase-II clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT06441643)
- 04 Sep 2024 Phase-II clinical trials in Open-angle glaucoma in USA (Ophthalmic) (NCT06441643)
- 11 Jun 2024 Alcon plans a phase II trial for Glaucoma and Ocular hypertension (Monotherapy) in USA (Ophthalmic) in September 2024 (NCT06441643)